П. А. Андоскин, А. К. Емельянов, Михаил Алексеевич Николаев, К. А. Сенкевич, В. П. Шилин, А. А. Тимофеева, А. Ф. Якимовский, Софья Николаевна Пчелина
{"title":"ВЛИЯНИЕ ДОФАМИНА ПЛАЗМЫ НА УРОВЕНЬ АЛЬФА-СИНУКЛЕИНА Ш45+-КЛЕТОК КРОВИ ПРИ БОЛЕЗНИ ПАРКИНСОНА","authors":"П. А. Андоскин, А. К. Емельянов, Михаил Алексеевич Николаев, К. А. Сенкевич, В. П. Шилин, А. А. Тимофеева, А. Ф. Якимовский, Софья Николаевна Пчелина","doi":"10.24884/1607-4181-2015-22-2-14-17","DOIUrl":null,"url":null,"abstract":"Metabolic impairment of alpha-synuclein protein is considered to be the central event in PDpathogenesis. Recent studies explored usage of alpha-synuclein in peripheral fluids as a biomarker of PD, however alpha-synuclein level in the CSF and plasma is considered to be affected by hemolysis. In order to avoid contamination of a lymphocyte fraction by erythrocytes, we have proposed an algorithm based on measurements of alpha-synuclein levels in the homogeneous CD45+ cell blood fraction. For this study we formed a group of PD patients (N=14) and a control group without the neurological disorders (N=17). We found an increase in the level of the total alpha-synuclein in CD45+ cells of PD patients compared to controls (p = 0,04), and revealed a direct correlation between the level of dopamine in plasma and level of total alpha-synuclein in CD45+ cells in the control group (r=0,71, p = 0,007).The level of alpha-synuclein in CD45+ cells could be suggested as possible PD biomarker.","PeriodicalId":31266,"journal":{"name":"Ucenye Zapiski SanktPeterburgskogo Gosudarstvennogo Medicinskogo Universiteta im Akad IP Pavlova","volume":"22 1","pages":"14-17"},"PeriodicalIF":0.0000,"publicationDate":"2015-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ucenye Zapiski SanktPeterburgskogo Gosudarstvennogo Medicinskogo Universiteta im Akad IP Pavlova","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24884/1607-4181-2015-22-2-14-17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Metabolic impairment of alpha-synuclein protein is considered to be the central event in PDpathogenesis. Recent studies explored usage of alpha-synuclein in peripheral fluids as a biomarker of PD, however alpha-synuclein level in the CSF and plasma is considered to be affected by hemolysis. In order to avoid contamination of a lymphocyte fraction by erythrocytes, we have proposed an algorithm based on measurements of alpha-synuclein levels in the homogeneous CD45+ cell blood fraction. For this study we formed a group of PD patients (N=14) and a control group without the neurological disorders (N=17). We found an increase in the level of the total alpha-synuclein in CD45+ cells of PD patients compared to controls (p = 0,04), and revealed a direct correlation between the level of dopamine in plasma and level of total alpha-synuclein in CD45+ cells in the control group (r=0,71, p = 0,007).The level of alpha-synuclein in CD45+ cells could be suggested as possible PD biomarker.